Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2024-08-10 Investor Presentation
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation for the First Quarter ended June 30, 2024' and is addressed to stock exchanges as per SEBI regulations. It contains detailed financial highlights, segment-wise revenue splits, consolidated profit & loss account, balance sheet, cash flow statement, and management commentary for Q1 FY25. The content is structured as a presentation with charts and commentary, focusing on financial results, business strategy, and market position. It is not a full annual or quarterly report with statutory financial statements but a detailed presentation aimed at investors. Therefore, it fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2024-08-10 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated August 10, 2024, announcing the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2024. It references Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of quarterly financial results. The document includes extracts of the financial results and mentions that the full detailed results are available on the stock exchange and company websites. The content is focused on quarterly financial results with actual financial data presented for the quarter ended June 30, 2024. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. The document is not merely an announcement of a report but contains actual financial data, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is IR with high confidence. Q1 2025
2024-08-10 English
Outcome of Board Meeting
Regulatory Filings
2024-08-09 English
Financial Result Updates
Regulatory Filings
2024-08-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is an invitation to an earnings call scheduled for August 12, 2024, to discuss the unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. It includes details about the call, participants, and registration information. The document does not contain actual financial data or detailed financial analysis but is rather a notice or invitation for the earnings call event. According to the classification rules, such a document is best classified as a Call Transcript (CT) only if it contains the full transcript of the call, which this does not. It is also not an Earnings Release (ER) because it does not announce financial results but invites to discuss them. The document is not a report publication announcement (RPA) because it is not announcing the release of a report but inviting to a call. The best fit is Call Transcript (CT) category as it relates to the earnings call event, but since it is only an invitation, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general regulatory announcement related to the earnings call. However, given the options and the nature of the document, the closest specific category is Call Transcript (CT) with moderate confidence, acknowledging it is an invitation rather than a transcript. Confidence is moderate at 0.7 due to the document being an invite rather than the transcript itself.
2024-08-07 English
Board Meeting — CONCORD BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 09-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for t…
Regulatory Filings
2024-07-31 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.